Autopsy report · NCT03138538

M8891 First in Human in Solid Tumors

“As part of a portfolio-level management of the company's oncology pipeline, it was decided to stop the next phase of internal development of the MetAP2 (M8891) program to enable realization of other opportunities within the oncology portfolio.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 1 month before it stopped.
• 27 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

EMD Serono Research & Development Institute, Inc.

Sponsor type

Industry

Conditions

Advanced Solid Tumors; Metastatic Renal Cell Carcinoma

Interventions

Part 1: M8891

Participants

27

Sites

7

Countries

United States

Trials that died the same way

• First in Human Study of M1069 in Advanced Solid Tumors
  “Overarching portfolio-level review of the company's oncology pipeline resulted in early termination of the study. The study was not terminated due to safety.” (61% match in meaning)
• Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China
  “Based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.